Protalex Inc.

Protalex Inc.
Stock Exchange Other OTC
Market Cap
$1.54 M
Shares Outstanding
47.33 M
Public Float
6.15 M


131 Columbia Turnpike
Florham Park New Jersey 07932
United States
Employees -
Updated 07/08/2019
Protalex, Inc. is a development stage company which focuses on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis. Its product includes PRTX-100, formulated with purified staphylococcal protein A, which is an immune modulating protein produced by bacteria. The company was founded by John E.


View All

Arnold P. Kling
President & Director
Kirk M. Warshaw
Chief Financial Officer, Secretary & Director